Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rossignol Patrick, Agarwal Rajiv, Canaud Bernard, Charney Alan, Chatellier Gilles, Craig Jonathan C, Cushman William C, Gansevoort Ronald T, Fellström Bengt, Garza Dahlia, Guzman Nicolas, Holtkamp Frank A, London Gerard M, Massy Ziad A, Mebazaa Alexandre, Mol Peter G M, Pfeffer Marc A, Rosenberg Yves, Ruilope Luis M, Seltzer Jonathan, Shah Amil M, Shah Salim, Singh Bhupinder, Stefánsson Bergur V, Stockbridge Norman, Stough Wendy Gattis, Thygesen Kristian, Walsh Michael, Wanner Christoph, Warnock David G, Wilcox Christopher S, Wittes Janet, Pitt Bertram, Thompson Aliza, Zannad Faiez
Аннотация
Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.